Amgen Inc.

John Laird Buchanan

Vinod Francis Patel

Xiaotian Zhu

Joseph J Nunes

Perry M Novak

Erin F DiMauro

Matthew W Martin

David Craig McGowan

Joseph L Kim

Jean-Christophe P Harmange

Stuart C Chaffee

William H Buckner

Craig E Masse

Lucian V DiPietro

Gregory J Habgood

Nagasree Chakka

Howard Bregman

Ning Xi

Andrew Stewart Tasker

Matthew M Weiss

Frank Kayser

Brian Lewis Hodous

Daniel Elbaum

Shon Booker

Yuan Cheng

Shimin Xu

Angel Guzman-Perez

Daniel La

Steven F Bellon

Russell Graceffa

Tae-Seong Kim

Julie Germain

Hakan Gunaydin

Deborah Choquette

Michele Potashman

Zihao Hua

Xin Huang

George Borg

Douglas A Whittington

Teresa L Marshall

Jean E Bemis

David M Armistead

Ryan D White

David John Kopecky

Rajiv Sharma

Xiaolin Hao

Hanh Nho Nguyen

Mario G Cardozo

Christopher Neil Farthing

Stephanie Geuns-Meyer

Sarah Lively

Jinqian Liu

Jiasheng Fu

Xiao Mei Zheng

Xian Yun Jiao

Bingfan Du

Hongbing Huang

Stephen J Shuttleworth

Alexander David Frenkel

Simon A Burkitt

Leticia M Toledo-Sherman

Martin J Harrison

Susan A Tomlinson

Simon Van Der Plas

Compounds of Formula I are useful inhibitors of tankyrase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein. 

Quinazolinone compounds and derivatives thereof

Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein. 

Oxazolidinone compounds and derivatives thereof

The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Carboxamides as inhibitors of voltage-gated sodium channels

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Compounds and methods of use

The present invention relates to furanopyrimidine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I. The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula I.

Furanopyrimidines

The present invention relates to compounds of Formula I or a stereomer, a tautomer, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof, pharmaceutical formulations containing the compounds, methods of treatments using the compounds, for example, protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders and methods of preparing medicaments comprising the compounds.

Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors

The present invention relates to pyrimidine or pyridine carbamate compounds having the general Formula I: and pharmaceutically acceptable salts or derivatives thereof. Also included are methods of treatment of various diseases and conditions, including inflammation, inhibition of T cell activation and proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, the methods comprising administering a therapeutically-effective amount a compound of Formula I, or a salt or derivative form thereof, as described above.

Substituted heterocyclic compounds and methods of use

The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.

Amino-substituted pyrimidinyl derivatives and methods of use

The invention relates to inhibitors of enzymes that bind to ATP or GTP and/or catalyze phosphoryl transfer, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making phosphoryl transferase inhibitor compounds, methods of inhibiting phosphoryl transferase activity, and methods for treating disease or disease symptoms.

Kinase inhibitors

The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.

Substituted pyrimidinyl derivatives and methods of use

The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer and polycystic kidney disease.

Substituted triazinyl acrylamide derivatives and methods of use

Growing community of inventors

Newton, MA, United States of America

John Laird Buchanan